Ivan Gergel, MD, MBA Chief Medical Officer & Managing Partner

Dr. Ivan Gergel has been Managing Partner and Chief Medical Officer at New Rhein since 2017. Ivan is an experienced global pharmaceutical R&D executive whose successes to date include 14 drug approvals. Ivan has held senior leadership positions in several U.S. companies and overseen teams in the development, approval, and commercialization of numerous new medicines. Prior to joining New Rhein, Ivan was CMO and Head of Drug Development for Nektar Therapeutics, Inc. From 2008 to 2014, Ivan served as Executive VP and Chief Scientific Officer of Endo Health Solutions. Ivan was at Forest Laboratories, Inc. from 1998 to 2008 where he was Senior VP of R&D and President of the Forest Research Institute.

From 1989 to 1998, he worked for SmithKline Beecham in the UK and the U.S. Ivan received his MD from the Royal Free Medical School, University of London, and his MBA from the Wharton School of the University of Pennsylvania. Ivan is a member of the Royal College of Psychiatrists and a fellow of the Faculty of Pharmaceutical Medicine of the UK College of Physicians. He presently serves on the board of Neuraptive Therapeutics, Inc., Butterfly Medical Ltd., Theranica, Alveus Therapeutics Inc., and is Chairman of Corsair Pharma. He has served on the boards of Corium International Inc., Realm Therapeutics, Neurotrope Inc., PA BIO, and of the PhRMA Foundation. Ivan served as a member of the Science and Regulatory Committee of PhRMA. He lives in Malvern, Pennsylvania and has three sons. Ivan plays tennis and misses playing cricket.